1. Macro Dashboard
| Indicator | Level | 5-Day Change | Signal |
|---|---|---|---|
| KOSPI | 5,882 | +7.0% | 5-day rally, internals weak |
| KOSDAQ | 750.1 | +0.2% | Flat |
| VIX | 17.0 | −12.7% | Calm |
| US 10Y | 4.99% | +0.09pp | Stable |
| USD/KRW | 1,338 | +0.9% | Mild KRW softness |
| Brent | $110.0 | −5.0% | Declining |
| DXY | 102.1 | +0.2% | Flat |
Regime: Korea = Bear / US = Bull. KOSPI (200-DMA: 6,480) and KOSDAQ (200-DMA: 974) both sit well below their long-term averages. Market breadth at 20.6% of stocks above the 50-DMA — below the 25% Bear threshold — confirms the regime despite the headline index recovery. US indices (NASDAQ, S&P 500) remain above 200-DMA with VIX at 17 and HY OAS tightening to 3.18%; the Bull label holds. Korean rates are easing at the margin (KTB 3Y: 3.80%, KTB 10Y: 4.11%), but the spread story does not yet override the breadth signal.
2. Market Wrap
Source: KR Market Snapshot (2026-10-29). No same-day full close briefing was available; market character is derived from the DB snapshot.
Today’s session was broadly negative beneath the surface. Of 2,593 names tracked, 1,793 declined against 542 advances. The ADR proxy came in at 30.2 and the average stock return hit −1.59% — the kind of internal weakness that makes the KOSPI headline a poor guide to what actually happened.
Construction and energy led the selling. 대우건설 (047040.KS) fell 18.57%, 한화솔루션 (009830.KS) −11.61%, LG에너지솔루션 (373220.KS) −8.60%, and SK이노베이션 (096770.KS) −7.09%. Crucially, foreign and institutional investors were aligned sellers in these names — a coordinated exit that differs from ordinary two-sided rotation.
Financials and data infrastructure attracted buyers. KB금융 (105560.KS) +1.82% and 삼성화재해상보험 (000810.KS) +2.20% were foreign net-buy names. Domestically, institutions accumulated 삼성SDI (006400.KS), 삼성생명 (032830.KS), 신한지주 (055550.KS), and 현대모비스 (012330.KS). 한화비전 (489790.KS) surged 22.14% on institutional buying against foreign selling — the day’s strongest single-name momentum. 케이아이엔엑스 (093320.KQ) +13.28% was another institutional pick in the data infrastructure theme.
Passive flow context: Program trading was a modest net +₩120bn; ETF net creation reached +₩1,151bn — a large inflow. But basis sits at −0.87, below the +1.0 threshold for passive-confirmed support. Large ETF inflows with negative basis suggest asset allocation rebalancing rather than directional conviction.
The session’s character: selective risk-off, with institutional rotation out of construction, batteries, and renewables into financials and infrastructure. In a Bear regime where only one in five stocks is above its 50-DMA, quality and earnings momentum are the few filters that matter.
3. Today’s Quality Re-Rating Candidates
Source: KR Meta Screener (2026-10-29), 88-ticker universe. The cross-screener overlap table shows no simple 2+ overlap pairs today; the meta screener ranks by independent evidence family count and family-capped scoring.
The framework’s editorial lens: good businesses where institutional money is entering and the market is beginning to reprice the earnings story.
Five names carry three or more independent evidence families. 티에프이 (425420.KQ) is the only name with all four layers — Quality Compounder + Smart Money Quality + Smart Money Earnings + Cycle Rerating — making it the highest-conviction setup in today’s screen.
Top Candidates
| Rank | Ticker | Name | Meta Score | Families | Screeners Hit | Key Metrics |
|---|---|---|---|---|---|---|
| 1 | 353200.KQ | Daedeok Electronics (대덕전자) | 57.2 | 5 | Quality, Cycle Rerating, PEAD | ROE 5.3%, OP YoY +336%, Δmargin +3.4pp |
| 2 | 072950.KQ | Bitsaem Electronics (빛샘전자) | 54.6 | 3 | Quality, Cycle Rerating, PEAD | ROE 9.6%, OP YoY +77%, Δmargin +1.5pp |
| 3 | 425420.KQ | TFE (티에프이) | 54.5 | 4 | Quality, Smart Money Quality, Smart Money Earnings, Cycle Rerating | ROE 16.6%, OP YoY +334%, Δmargin +11.1pp |
| 4 | 086450.KQ | Dongkuk Pharma (동국제약) | 54.4 | 5 | Quality, Cycle Rerating, PEAD | ROE 9.9%, OP YoY +20%, Δmargin +0.5pp |
| 5 | 080580.KQ | Okins Electronics (오킨스전자) | 53.2 | 3 | Quality, Cycle Rerating, PEAD | ROE 15.4%, OP YoY +482%, Δmargin +8.9pp |
| 6 | 252990.KQ | SEM C&S (샘씨엔에스) | 52.2 | 5 | Quality, Cycle Rerating, PEAD | ROE 9.7%, OP YoY +183%, Δmargin +9.1pp ⚠️ |
| 7 | 089890.KQ | Cosses (코세스) | 37.9 | 5 | Cycle Rerating, PEAD, Consensus Up | Δmargin +29.2pp, DART contract catalyst |
| 8 | 021240.KS | Coway (코웨이) | 37.4 | 4 | Quality, RS80 Not-Late | ROE 17.1%, earnings preview filed Oct 29 |
| 9 | 003380.KS | Harim Holdings (하림지주) | 35.5 | 3 | Cycle Rerating, RS80 Not-Late | Spin-off catalyst (DART Oct 26) |
| 10 | 089860.KS | Lotte Rental (롯데렌탈) | 34.5 | 3 | Cycle Rerating, RS80 Not-Late | 20D flow +11.2%, Focus Candidate |
⚠️ 샘씨엔에스: Net foreign+institutional selling −₩17.4bn absorbed by retail +₩8.4bn. Monitor whether institutional selling persists post the Oct 27 preliminary earnings disclosure.
Deep-Dives: Top 3
1. Daedeok Electronics (대덕전자, 353200.KQ) — Operating Leverage Meets Official Catalyst
Daedeok is a PCB substrate manufacturer in Korea’s semiconductor packaging supply chain. Five independent evidence families at a meta score of 57.2 place it at the top of today’s queue. The operating leverage story is blunt: OP YoY +336%, margin expansion +3.4pp, with ROE rebuilding from a low base to 5.3%. The stock sits 27.6% below its 52-week high and 14.9% above the 50-DMA, leaving drift room intact. A DART IR event was filed Oct 23 — the catalyst layer is present. The caution is meaningful: net foreign+institutional selling of −₩6.3bn over five days signals sophisticated holders using strength to exit. The key question is whether the IR event reverses that flow or accelerates it.
2. TFE (티에프이, 425420.KQ) — All Four Layers, Institutional Absorption
TFE makes semiconductor test handler equipment. This is the only name today with the full four-layer stack — Quality Compounder, Smart Money Quality, Smart Money Earnings, and Cycle Rerating — which is the most complete signal structure the framework can produce. The fundamentals confirm it: ROE 16.6%, OP YoY +334%, and margin expansion of +11.1pp indicate a business deep in an earnings inflection. The flow pattern is equally clear: foreign and qualified institutional investors bought a net +₩14.3bn over five days while retail sold −₩15.8bn. That’s institutional accumulation against retail distribution — one of the framework’s cleanest money-flow setups. A large-holding disclosure was filed at DART on Oct 23. Next check: whether the five-day +₩14.3bn buying pace continues or was a block repositioning.
3. Dongkuk Pharmaceutical (동국제약, 086450.KQ) — Defensive Compounder in a Risk-Off Session
Dongkuk Pharmaceutical is a domestic pharma and nutraceutical company with a long record of steady compounding. It scores on five evidence families including fundamental quality, cycle rerating, and post-earnings drift. OP YoY at +20% is the lowest of the top five — but on a healthcare platform with recurring revenues, consistent margin expansion (+0.5pp) and ROE of 9.9% make it a defensive quality candidate. Foreign and institutional investors absorbed retail selling of −₩6.2bn, suggesting quiet accumulation. A shareholder meeting has been called (DART Oct 12); if strategic restructuring is on the agenda, the catalyst layer strengthens. In a session where construction and batteries are being sold indiscriminately, healthcare compounders with earnings improvement are a logical destination for repositioning capital.
Screener data as of 2026-10-29. Financial figures carry varying filing lags; most DART-sourced fundamentals are from Q4 2025 filings. These names are research candidates for further investigation, not investment recommendations.